Video Shorts

1:04
GLP-1 Agonists Could Help Address Rising Rates of Early-Onset CRC
3 months ago
by
Colton Jones, MD

0:58
A New Era for RAS Inhibition in PDAC: From an “Undruggable” Target to a Potential Paradigm-Shifter
3 months ago
by
Brian M. Wolpin, MD, MPH

1:46
Breaking Down the Use of FES-PET/CT in Breast Cancer
3 months ago
by
Megan Kruse, MD

2:10
The Push for Individualized Risk-Stratification Strategies in Myeloma
3 months ago
by
C. Ola Landgren, MD, PhD

1:05
Is Surgery Still the Cornerstone of Curative Treatment in Esophageal Cancer?
3 months ago
by
Peter C. Enzinger, MD, Dana-Farber Cancer Institute

1:05
Spotlighting Evolutions in HER2+ Breast Cancer Management
3 months ago
by
Sara M. Tolaney, MD, MPH

1:54
Examining the Treatment Landscape of Muscle-Invasive Bladder Cancer
3 months ago
by
Matthew D. Galsky, MD

4:03
OncLive News Roundup for the Week of 4/19
3 months ago
by
Chris Ryan

1:00
Discussing the Rationale for Evaluating a ROR2-Targeting ADC in OPSCC
3 months ago
by
Alan L. Ho, MD, PhD

1:18
Highlighting the Importance of Testicular Cancer Awareness
3 months ago
by
Mina M. Fam, MD

1:04
Could GLP-1 Receptor Agonists Help Reduce CRC Risk Beyond Weight Loss?
3 months ago
by
Colton Jones, MD

2:07
Navigating Long-Term Care Following CAR T-Cell Therapy in Myeloma
3 months ago
by
Jesús Berdeja, MD

1:47
How Community Helps Oncology Professionals Achieve Work-Life Harmony
3 months ago
by
Timothy I. Shaw, PhD

0:53
Darlifarnib in Clear Cell Renal Cell Carcinoma
3 months ago
by
Adanma Ayanambakkam, MD, MS

1:20
Why Palliative Care Needs to Start Earlier for AYA Patients With Sarcoma
3 months ago
by
Vinayak Venkataraman, MD

2:09
Treatment Considerations Following Covalent BTK Inhibitors in CLL
3 months ago
by
Alexey V. Danilov, MD, PhD

1:22
Highlighting the NCCN Advocacy Academy Program
3 months ago
by
Alyssa Schatz, DrPH, MSW

2:35
Selecting Second-Line Therapy in R/R Myeloma
3 months ago
by
Noopur S. Raje, MD

0:55
Staging Pitfalls in Esophageal Cancer Could Alter Curative Intent Decisions
3 months ago
by
Peter C. Enzinger, MD, Dana-Farber Cancer Institute

0:42
The Potential Role of Tumor-Informed ctDNA Testing in Early TNBC
4 months ago
by
Marija Balic, MD, PhD

1:20
Should We Prescribe Exercise Like We Prescribe Chemotherapy in Sarcoma?
4 months ago
by
Vinayak Venkataraman, MD

4:12
OncLive News Roundup for the Week of 4/12
4 months ago
by
Chris Ryan(+1 more)

0:45
How Should Bone Pain Be Interpreted in Patients With Cancer on Bone-Modifying Agents?
4 months ago
by
R. Lor Randall, MD, FACS

1:02
Raising Awareness for PD-L1 Testing for Head and Neck Cancer
4 months ago
by
Fangdi Sun, MD

0:36
Safely Incorporating Integrative Medicine Into Breast Oncology
4 months ago
by
Lillian Rodich, MSPAS, MPH

0:24
Examining the Potential Role of ctDNA-Guided Therapy in RCC
4 months ago
by
Taigo Kato, MD, PhD

0:44
Highlighting the Importance of PD-L1 Testing for Head and Neck Cancer
4 months ago
by
Ranee Mehra, MD

1:13
Spotlighting the Future of Triple-Negative Breast Cancer Management
4 months ago
by
Rena D. Callahan, MD

0:41
Targeting CALR Mutations in Myeloproliferative Neoplasms
4 months ago

2:51
Recapping the Most Important Data and Developments From SGO 2026!
4 months ago
by
Caroline Seymour(+2 more)
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Rituximab Biosimilar for Hematologic Malignancies
2
Talk of Cure, a New ADC, and a Negative Trial: Breaking Down the Biggest Gynecologic Cancer News From ASCO 2026
3
Emerging Maintenance Strategies May be the Key to Extending Survival in ES-SCLC
4
Phase 1 Data Set the Stage for Further Exploration of Cevostamab in R/R Myeloma
5
